BCTX News & Events

BriaCell Therapeutics announces that the independent Data Safety Monitoring Board, DSMB, has issued its sixth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell's ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer.

BriaCell Therapeutics announces clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC, and one poster highlighting further analyses of Phase 2 data. Key highlights: Final Phase 2 Bria-IMT median overall survival is 16.6 months; Positive Quality of Life data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer patients; Biomarker analyses from the ongoing Phase 3 study confirm predictors of anti-cancer response seen in Phase 2

"We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next generation personalized immunotherapy candidate for prostate cancer," said William Williams, president and CEO.

BriaCell Therapeutics has added Penn Medicine's Abramson Cancer Center as a clinical trial site in its ongoing pivotal Phase 3 study evaluating Bria-IMT in combination with an immune checkpoint inhibitor versus physician's choice of treatment in advanced breast cancer. Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners. The Bria-IMT combination regimen has received FDA Fast Track designation.